arrow
Z

Zachary A. Cooper

AstraZeneca
H指数:55
被引数:2.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Retraction Note: sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance

撤稿说明:sFRP2在衰老微环境中驱动黑色素瘤转移和疗法抵抗

Nature
IF48.5
2025-10-290
OAAI
COLUMBIA-1: a randomised study of durvalumab plus oleclumab in combination with chemotherapy and bevacizumab in metastatic microsatellite-stable colorectal cancer

COLUMBIA-1: durvalumab联合oleclumab联合化疗和贝伐单抗治疗转移性微卫星稳定结直肠癌的随机研究

2024-07-250
OA
Preclinical evaluation of a novel B7-H4 targeted antibody-drug conjugate AZD8205 as a single agent and in combination with novel PARP inhibitor and checkpoint blockade
2023-04-040
PRE
Design and Preclinical Evaluation of a Novel B7-H4-Directed Antibody-Drug Conjugate, AZD8205, Alone and in Combination with the PARP1-Selective Inhibitor AZD5305
2022-11-1030
OA
Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy
Nature
IF48.5
2022-06-150
PRE
Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in Braf-mutated melanoma
2021-11-069
OA
Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade

肠道菌群特征与联合CTLA-4和PD-1阻断的毒性有关

2021-07-08251
OAAI
Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumors
2020-10-0931
OAAI
Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma

空间分辨分析将基因组和免疫多样性联系起来,揭示黑色素瘤中不利的中性粒细胞活化

2020-04-1515
OAAI
The human tumor microbiome is composed of tumor type–specific intracellular bacteria

人类肿瘤微生物组由肿瘤类型特异性细胞内细菌组成

Science
IF45.8
2020-01-010
OAAI
Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies
2019-09-11141
OAAI